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Genetic predisposition to childhood cancer has been borne out 
by retinoblastoma which proved to be a paradigm for hereditary
cancers (Knudson, 1971). Li–Fraumeni syndrome (LFS), a
multiple cancer syndrome characterized by a wide spectrum of
neoplasms, documented a further hereditary cancer condition likely
to affect children (Li et al, 1988; Varley et al, 1997b). The defini-
tion of LFS proposed by Li and Fraumeni specifies that the
proband is diagnosed as having sarcoma before 45 years of age,
and also has a first-degree relative with cancer before 45 years of
age and another first- or second-degree relative with any cancer
diagnosed during this age interval or sarcoma occurring at any age.
The most prevalent malignancies observed in LFS include: soft
tissue sarcoma, osteosarcoma, brain tumours, adrenocortical carci-
noma, leukaemia and breast cancer. Germline mutations in the p53
tumour suppressor gene have been associated with a predisposi-
tion to these cancers in families affected by LFS (Malkin, 1994).
Fifty to 70% of LFS families display a p53 mutation (Brugières et
al, 1993; Birch et al, 1994; Frébourg et al, 1995; Varley et al,
1997a), which signifies that mutation screening may have over-
looked alterations that affect regulatory regions and not p53
coding sequences and/or that germline mutations of other gene(s)
may be responsible for LFS. Germline p53 mutations have also
been detected in families presenting tumours outside the spectrum
typifying LFS (Malkin et al, 1992; Toguchida et al, 1992). Studies
on individuals with typical LFS tumours but not previously
selected on family history, have yielded frequencies of germline
p53 mutation that vary with age and tumour types (Varley et al,
1999). None of these studies permitted an estimation of cancer risk
in mutation carriers, although some unaffected carrier relatives
may be found in family studies. Indeed, selection criteria for LFS
are so stringent that correction for selection bias is impossible.
Even looser criteria, such as Li–Fraumeni-like (LFL) (Eeles,
1995) or Li–Fraumeni incomplete (LFI) (Brugières et al, 1993) do
not allow correction for ascertainment bias. This is why we under-
took a study at the Institute Gustave Roussy with loose criteria
which offer two advantages: (i) they do not imply the existence of
highly penetrant susceptibility genes and therefore do not neces-
sarily prohibit the detection of mutations associated with low
cancer risk, (ii) correction for selection bias is possible for the
estimation of cancer risks in individuals.
MATERIALS AND METHODS
Patients, family history and blood samples
The family history of cancer of children under 18 years treated 
for all types of solid malignant tumours in the Department of
Paediatric Oncology at the Institute Gustave Roussy in Villejuif
(France) has been investigated since January 1991. To minimize
possible bias due to genetic and environmental heterogeneity, non-
white children were excluded. Information was collected through a
direct interview with a trained counsellor from families of patients
treated in the Department after 1991. Information was obtained via
a mailed questionnaire and completed in most cases by a telephone
interview, for patients treated before that period but who were no
longer followed up.
Family data were collected through the proband’s parents. They
included information on each of the proband’s first- and second-
degree relatives and first cousins. When necessary, additional
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were contacted for a telephone interview. Information on relatives
included general characteristics (sex, date of birth, malformations,
date and cause of death) and the occurrence of any cancer. When
cancers had occurred, confirmation of the diagnoses and age at
onset were sought in medical and pathology records. Only inva-
sive cancers were considered, excluding non-melanoma skin
cancer and in situ carcinoma. Informed consent was obtained from
parents before inclusion in the study.
A subgroup of children with a putative increased frequency of
susceptibility genes, was defined on the basis of the occurrence of
either of the following criteria: (i) at least one cancer case affecting
a first- or second-degree relative or a first cousin before the age of
46 (‘familial cases’), (ii) multiple primary cancers in the proband
regardless of their family history (‘multiple tumour cases’).
Blood samples were obtained from the proband, his/her parents
and, when a relative was affected, from all the available family
members in that branch of the pedigree. Specific informed consent
for blood sampling was obtained from all participating relatives.
This study received the approval at the local ethics committee
(CCPPRB, Kremlin-Bicêtre).
Genotyping p53
p53 was genotyped in peripheral lymphocytes isolated from fresh
blood samples. Direct sequencing was used for the first set of 
100 samples. Genomic DNA was amplified as three fragments
including respectively exons 2–4, exons 5–8 and exons 9–11.
Polymerase chain reaction (PCR) primers sequences are available
on request. Genotyping was subsequently carried out with a
functional assay in yeast (FASAY), as described by Ishioka et al,
(1993), and modified by Flaman et al (1995). Vent DNA poly-
merase (New England Biolabs) was used to amplify p53 reverse
transcripts before transfection in yeast. Yeast colonies carrying a
p53 mutant allele were identified either as His-auxotroph, or as red
colonies. p53 cDNA was extracted from mutant colonies and
sequenced. The FASAY has been reported to reveal over 90% of
p53 mutant alleles (Flaman et al, 1995) as did direct sequencing of
amplified p53 exons scores in our hands.
Estimation of cancer risk
The risk of cancer for individuals carrying a p53 mutation was
estimated using ARCAD, a maximum likelihood method and a
program based on a survival analysis approach in which the event
considered is age at onset of cancer (Le Bihan et al, 1995). For
each individual, the information used is the genotype (carrier or
not), and the phenotype which includes the affection status and the
age of onset for affected individuals and the age at examination for
unaffected ones. The likelihood L for a sample of n families is the
product of likelihoods of each family f:
To allow correction for ascertainment of families, Lf is the ratio of
a numerator Nf, the contribution of a family f to the likelihood
corrected by a denominator Df for ascertainment. The likelihood
may be written as a function of the different parameters xj
G, the
risk for a mutation carrier (genotype G) of being affected in age-
class j, given that he(she) was unaffected in the preceding class,
and the corresponding xj
g for the non-carrier individuals (genotype
g). This different xj
G are the estimated parameters and the xj
g were
computed from, French population statistics (Benhamou et al,
1990; De Vathaire et al, 1996).
This method takes into account and corrects for three sources of
bias due to selection criteria, namely (i) an excess of tumours
before the age of 16, because the family was ascertained through an
affected child, (ii) an excess of tumours before the age of 46,
because at least one affected relative was requested, (iii) a deficit of
individuals affected at a young age because most of the proband’s
parents and grandparents had reached a reproductive age without
cancer. The denominator Df is the probability that the family f could
be selected, i.e. the probability that there is a proband and that at
least one relative is affected and that parents and grandparents were
not affected before they reached a reproductive age.
A major advantage of this method is that it can use information
on all family members including those in whom testing could not
be performed. In the latter case, information is provided through
their relationship with p53 mutation carriers. The risks are esti-
mated separately for men and women, and the equality of risks
between sexes is tested using the classic homogeneity test based
on maximum likelihood (ML).
The denominator in the paper by Le Bihan et al (1995) was
computed on the hypothesis that these three events were indepen-
dent. In fact, events 1 and 3 are not totally independent and the
program was modified to take this into account which, however,
did not change the results (the accurate computation is available on
request).
RESULTS
Families
Among the 2691 families investigated from January 1991 to May
1997, 295 fulfilled the selection criteria and gave their informed
consent for DNA analysis. Twenty-seven children were excluded
from the molecular analysis because they were affected by a
genetic condition known to be linked to a gene other than 
p53: neurofibromatosis type 1, Beckwith–Wiedeman syndrome,
WAGR syndrome, Gorlin syndrome and familial adenomatous
polyposis. Finally, 252 ‘familial cases’ and 16 ‘multiple tumour
cases’ fulfilling the selection criteria could be analysed. The diag-
nosis of cancer was confirmed by the medical and/or pathology
records in 73% of the affected relatives.
Case distribution according to selection criteria is given in Table
1. Among familial cases, we have indicated whether they fulfilled
the classic LFS criteria, or incomplete criteria (LFI defined as
aggregation of typical LFS cancer lacking one of the classic
criteria, no sarcoma in the proband, no first-degree relative affected
or only one relative affected under the age of 45), or had multiple
tumours without a family history. Table 2 presents the distribution
of cases according to tumour type and date of diagnosis.
Genotyping p53
For the first hundred samples p53 was genotyped by direct
sequencing and subsequently by functional assay in yeast.
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n
L = PLf
f = 1Seventeen p53 germline mutations were identified and are listed in
Table 3. Eight mutations were detected by direct sequencing in the
first set of 100 samples. These mutants were subsequently assayed
in yeast: six scored positive, two negative, with the latter including
mutation segregation in family no. 7 leading to a null allele
(absence of mature mRNA in the cytoplasm), and mutation segre-
gation in family no. 108 (Arg337His) which lies within the
oligomerization domain but does not affect the transactivation
capacity of p53. Nine mutations were detected among the 168
samples tested directly by the functional assay.
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Table 1 Cases according to selection criteria and family status and proportion of p53 germline mutation
Syndrome Mutant Wild-type Total Mutation (%)
Familial cases LFS 8 8 16 50.0
LFI 4 62 66 6.1
Other 4 166 170 2.3
Multiple tumoursa 1 15 16 6.2
Total 17 251 268 6.3
a Without a family history. LFS: Li–Fraumeni syndrome; LFI: incomplete Li–Fraumeni syndrome.
Table 2 Distribution of cases according to tumour type
Diagnosisa Proband Proband Total p53
studied studied mutation
before since 1991
1991
Soft tissue sarcoma 40 14 54 6 (11%)
Osteosarcoma 12 7 19 3 (15.8%)
Brain tumour 18 25 43 4 (9%)
Adrenocortical carcinoma 1 2 3 2 (66.7%)
Non-hodgkin’s lymphoma 27 11 38 0
Ewing’s sarcoma 3 3 6 0
Hodgkin’s disease 15 2 17 0
Neuroblastoma 33 13 46 2 (4%)
Nephroblastoma 20 1 21 0
Germ cell tumour 12 4 16 0
Other 3 2 5 0
Total 184 84 268 17
a In case of multiple tumours the individuals are classified according to the first one.
Table 3 Germline mutations in the p53 gene
Family no. Exon no. Position Mutation Consequence Status Detection
codon no.
1975 Intron 4/ [126–132] Addition G within ® alternative splicing De novo Yeast+Sequence
Exon 5 splice acceptor site ® In phase deletion [126–132]
2471 4 125 ACG®ACC retention 109 bp from intron 4 Inherited Yeast+Sequence
54 5 158 CGC®GGC Arg®Gly Inherited Sequence+Yeast
11 5 175 CGC®CAC Arg®His Inherited Yeast+Sequence
7c 6 deletion AGT®AG Frameshift®214 bona fide Inherited Sequence
within 215 + 31 illegitimate residues
151b 7 248 CGG®TGG Arg®Trp Inherited Sequence+Yeast
1128 7 245 GGC®AGC Gly®Ser De novo Yeast+Sequence
2453 8 [264–265] del ACT In phase deletion Leu#264 Inherited Yeast+Sequence
231b 8 273 CGT®GGT Arg®Gly Inherited Sequence+Yeast
66 8 273 CGT®CAT Arg®His Inherited Yeast+Sequence
867b 8 282 CGG®TGG Arg®Trp Inherited Sequence+Yeast
1497 8 282 CGG®TGG Arg®Trp Inherited Sequence+Yeast
2454 8 273 CGT®TGT Arg®Cys Inheriteda Yeast+Sequence
2028 8 282 CGG®CAG Arg®Gln Inherited Yeast+Sequence
147 8 273 CGT®CTT Arg®Leu De novo Sequence+Yeast
641 8 281 GAC®GTC Asp®Val De novo Yeast+Sequence
108 9 337 CGC®CAC Arg®His Inherited Sequence
Yeast: mutation detectable by the yeast assay. aInherited status highly probable. bAlready described in Brugières et al (1993). cAlready described in Stolzenberg
et al (1994).As shown in Table 1, eight mutations were detected in 16 of the
LFS families (50%), four mutations in 66 LFI families (6.1%); one
mutation was detected among 16 cases of multiple tumours
without a family history (6.2%) and four mutations in ‘other’ cases
of cancer aggregation (2.3%).
The tumours affecting probands shown to be p53 mutation
carriers, as shown in Table 4, belong to the LFS spectrum, except
for two cases of neuroblastoma. One of these children, however,
developed a secondary osteosarcoma which does belong to the
LFS spectrum. Among the child carriers with a brain tumour, there
were two cases of choroid plexus carcinoma, a rare tumour already
described in classic LFS (Jolly et al, 1994) and two cases of
medulloblastoma which is not considered a classic LFS malig-
nancy. Of the children having survived the first cancer, eight (five
probands and three relatives) developed at least one second malig-
nancy, two within the radiation field. Two to 11 (median 5) rela-
tives were tested in families with inherited mutations. Eleven
unaffected mutation carriers were detected, seven male individuals
aged 22–62 (median 41) and four females aged 5–42.
Hereditary transmission of the mutant allele from one parent
was demonstrated in 12 of the 17 mutations and was highly prob-
able in one family in which the putative parent carrier had died and
his affected relatives could not be tested (family no. 2454). In four
cases, failure to demonstrate the presence of a mutation in any of
the parents, led to the conclusion that the germline mutation had
been acquired from a de novo mutated germ cell. In these four
cases, genotyping, with two highly informative minisatellite
markers, was consistent with true paternity status.
Cancer risk estimates
The estimation of cancer risks was based on the 13 families in
which the p53 mutation segregated. Nearly all cancer diagnoses
were confirmed in these families (29/30 = 97%, among early-onset
p53 germline mutations in childhood cancers 1935
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Table 4 Families with p53 mutation
Family no. Tumour type Second tumour Cancer in relatives Type
Sex/Age at diagnosis (years) Age at diagnosis (years) Age at diagnosis (years)
147 ADCC (F/1) RMS (1) Mult t
641 Osteo (M/18) MC breast (29) Other
1128 Choroid plexus carcinoma (M/4) MA ovarian (30) Other
1975 Medulloblastoma (M/10) MC neuroblastoma (7) Other
2028 Neuroblastoma (F/1) MA lymphoma (44) Other
151 RMS (M/2) Osteo (20 y) M breast (41) LFI
sarcoma (52)
867 STS (M/14) Osteo (28 y) S RMS (1) LFI
Lung (30 y) brain (22)
breast (27)
108 ADCC (F/4) PU brain (33) LFI
2454 Osteo (M/17) PGM bilateral breast (42) LFI
7 RMS (M/3) Osteo (11) M breast (34) LFS
B ADCC (11)
231 RMS (F/1) B brain stem tumour (4) LFS
S ALL (6)
54 Osteo (M/11) M breast (29) LFS
B RMS (2)
11 RMS (M/2) Osteo (13) M breast (29) LFS
MA fibrosarcoma (6)
1497 Choroid plexus carcinoma (M/9) F lung carcinoma (40) LFS
PA breast (33)
PC medulloblastoma (14)
sarcoma (22)
2453 RMS (F/7) B NHL (11) LFS
S glioblastoma (25)
M breast (39)
MGM breast (30)
MU kidney sarcoma (25)
MA breast (43)
MC stomach (36)
MC breast (27)
MC bilateral breast (29)
MC breast (30)
N ADCC (3)
66 Neuroblastoma (M/5) Osteo (11) PGM NHL (42) LFS
Osteo (13) PA sarcoma (21)
PC ADCC (5)
PC brain (6)
2471 Ependymoma (M/2) M osteo (33) LFS
MA breast (40)
RMS: Rhabdomyosarcoma, ADCC: Adrenocortical carcinoma, STS: Soft tissue sarcoma, Osteo: Osteosarcoma, M: Mother, F: Father, B: Brother, S: Sister,
PGF: Paternal grandfather, PGM: Paternal grandmother, MA: Maternal aunt, PA: Paternal aunt, PU: Paternal uncle, PC: Paternal cousin, MC: Maternal cousin,
LFS: Li–Fraumeni syndrome, LFI: Incomplete Li–Fraumeni syndrome, Mult t: multiple tumours.cases and 2/4 = 50% among late-onset cases). The unconfirmed
cases were excluded from the analysis.
The risks (probability of being affected in a given age-class, if
unaffected in the preceding age category) are shown for each age-
class in Table 5, where males and females are separated and then
pooled. The risks in childhood are 19% for male and 12% for
female children with an overall risk of 15%. The corresponding
penetrance (probability of being affected before the end of the age-
class) by age 16, 45 and 85 are respectively 19%, 41% and 73% in
males, and 12%, 84% and 100% in females. In the older age-class
(>45), only the p53 carriers who were not affected before 46 (i.e
very few individuals and particularly females) provided informa-
tion for these estimates. The lack of information in females leads to
a large (0.00–1.00) confidence interval in this age-class. The pene-
trance is higher in females than in males (P < 0.05) and particularly
in the 16–45 age-class, almost entirely because of breast cancer
which represents 80% of all cancer cases in this age-class.
DISCUSSION
The functional assay in yeast is a powerful method for the detec-
tion of mutations affecting the transactivation capacity of p53.
Flaman et al (1995) demonstrated its ability to detect 90% of
germline p53 mutations. In this study, the assay overlooked two
mutations (not significantly different from the 10% reported): a
mutation leading to a null allele and a mutation (Arg337His) lying
within the oligomerization domain but obviously not affecting the
transactivation capacity of p53. That the latter may represent a rare
polymorphism cannot be ruled out, although this mutation has 
not been observed in more than 200 random alleles tested in this
laboratory. An alternative missense mutation targeting codon 337
(Arg337Cys) has been reported in a LFL family. This mutation
results in a protein which partially inhibits transactivation in the
FASAY (Lomax et al, 1997). By contrast, a mutation (Leu344Pro)
in close vicinity to this site, reported in a LFS family, gives rise to
a totally defective protein in the FASAY (Varley et al, 1996). Our
observation indicates that the loss of p53 transcriptional activity, at
least in the FASAY, is not a prerequisite for bringing about heredi-
tary predisposition to cancer within LFS.
In this study, we used far less stringent criteria than those
defining LFS, in order to allow the detection of germline p53
mutations with low penetrance. In spite of these criteria, most of
the mutations were found in families with a high aggregation of
cancers. Nonetheless, unaffected carriers were observed and there-
fore the existence of families with low penetrance cannot ruled
out. Varley et al (1999) also observed several unaffected carriers
among the relatives of children with adrenocortical tumours not
selected on family history. It is noteworthy that the detection of
either unaffected carrier parents or de novo mutations in probands
is favoured considering the poor prognosis of this disease. As a
matter of fact, de novo mutations have occasionally been reported
(Toguchida et al, 1992; Felix et al, 1993; McIntyre et al, 1994;
Speiser et al, 1996). The selection criteria used in our study were a
priori conducive to the detection of inherited cases. In spite of this,
de novo mutations were observed in three of 188 index cases with
only one affected relative and in one with multiple cancers (1.6%),
indicating that de novo mutation is not a rare event. In fact, this is
not unexpected considering the limited fecondity of the affected
p53 mutation carriers.
It is remarkable that two de novo mutations were found among
‘familial cases’. Indeed, including affected first cousins for the
selection of families, increases the probability of chance aggrega-
tion of sporadic cases. When such families are excluded from the
selection criteria for mutation analysis, 233 ‘familial cases’
remain. The distribution of mutations among tumour types and
types of family aggregations is virtually unchanged (data not
shown).
Our study is consistent with previous reports which indicate that
multiple tumours are frequent in germline p53 mutation carriers
(Malkin et al, 1992; Eeles et al, 1993; Felix et al, 1993; Scott et al,
1993; Gutiérrez et al, 1994). Many of these tumours occurred in a
radiation field, provoking concern about the risk associated with
radiotherapy in these children. We did not exclude patients
suspected of having therapy-induced malignancies in this study
since radiation and familial factors were shown to be independent
risk factors for the occurrence of second tumours (Kony et al, 1997).
As this sample represents a hospital-based population of child-
hood cancers, it is probably not strictly representative of all child-
hood cancers in the French population. Furthermore, there may be
a deficit of tumours with a poor prognosis since blood samples
were obtained only from alive children. This deficit is particularly
marked in brain tumours as shown on Table 2. However, this
should not impact on the cancer risk estimates since the method is
independent of selection on tumour type. In addition, there could
be a slight bias in favour of families with multiple affected
members, but the robustness of the method has been proven with
respect to this kind of bias when the risks are high (Le Bihan and
Bonaïti-Pellié, 1994).
The confidence intervals of the penetrances estimated here are
somewhat large, but this is due to the small number of families
with p53 germline mutation. Nonetheless, it can be firmly stated
that such penetrances are high, but not complete. The risk in child-
hood is slightly lower than previously published (Le Bihan et al,
1995) because of the correction of the computer program which in
its first version tended to overestimate the risk in the first age-
class. It is noteworthy that family ascertainment through child-
hood cancer may lead to select mutations with a particularly high
risk of cancer at a young age. Interestingly, our estimates are quite
consistent with those obtained from segregation analysis of fami-
lies of children with soft tissue sarcoma (Lustbader et al, 1992;
Strong et al, 1992) or through the follow-up of members of fami-
lies with LFS (Garber et al, 1991). The older age category did not
contribute much to the estimate of penetrance because of a limited
amount of data in this age-class, and essentially the two age-
classes (< 16 and 16–45) contribute to the likelihood of the
hypotheses of respectively equal and different penetrance in males
and females. The consequence of the difference between sexes is
extremely important since the risk of developing cancer after
childhood would mostly concern breast in women and would
decline for men as they become older.
In conclusion, this study associates a complete family history
investigation in a very large hospital-based population of children
1936 A Chompret et al
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Table 5 Risks of cancer in p53 mutation carriers according to age and sex
Age (years) Males Females Overall
0–15 0.19 (0.09–0.35) 0.12 (0.05–0.27) 0.15 (0.08–0.27)
16–45 0.27 (0.12–0.52) 0.82 (0.42–0.96) 0.54 (0.37–0.71)
>45 0.54 (0.07–0.95) 1.00 (0.00–1.00) 0.68 (0.14–0.97)p53 germline mutations in childhood cancers 1937
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with a biological investigation in a subgroup selected with
defined criteria. It demonstrates that only a small proportion of
these cases can be ascribed to an inherited germline p53 muta-
tions. It provides the first reliable estimations of cancer risks in
p53 carriers and shows that these risks are very high. This study
emphasises the existence of de novo mutations implying that
germline mutations can be found in children with no or a limited
family history.
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